OBJECTIVE: To evaluate the association between adherence to drugs and morphologic alterations (MOA) in a cohort of HIV-infected patients on HAART. METHOD: This was a cross-sectional multicenter cohort study in eight tertiary Clinical Centers of Northern and Central Italy. Consecutive outpatients taking HAART were enrolled from August 2000 to March 2001. They completed a self-administered questionnaire for the evaluation of signs of MOA and the self-reported adherence to drugs. Main outcome measures were MOA according to the Multicenter AIDS Cohort Study (MACS) definition and adherence to drugs. RESULTS: One hundred seventy-five persons were enrolled into the study. Median CD4 cell count was 522 (interquartile range [IQR] 306-720); 35% of people had undetectable HIV RNA. Patients had been taking HAART for a median of 53 months (IQR 33-62). Among enrolled patients, 83 (47%) had a diagnosis of self-reported MOA; 57 of them reported body changes of more than 12 months duration. Forty persons (23%) self-reported nonadherence in the previous week. Mean time on HAART was 48.7 months (SD = 19.7) for people with MOA and 42.1 months (SD = 21.8) for those without MOA (p =.043). The odds of adherence for people with MOA was 2.36 times (95% CI 1.11-5.00) higher than for people without MOA. On multivariate analysis, being older and female, having an undetectable HIV RNA, longer duration on HAART, and self-reported adherence were independently associated with the presence of MOA. In people with MOA, adherence seems to decrease over time. CONCLUSION: Longer time on HAART and self-reported adherence were correlated to MOA. MOA was also associated with older age and female gender.
OBJECTIVE: To evaluate the association between adherence to drugs and morphologic alterations (MOA) in a cohort of HIV-infectedpatients on HAART. METHOD: This was a cross-sectional multicenter cohort study in eight tertiary Clinical Centers of Northern and Central Italy. Consecutive outpatients taking HAART were enrolled from August 2000 to March 2001. They completed a self-administered questionnaire for the evaluation of signs of MOA and the self-reported adherence to drugs. Main outcome measures were MOA according to the Multicenter AIDS Cohort Study (MACS) definition and adherence to drugs. RESULTS: One hundred seventy-five persons were enrolled into the study. Median CD4 cell count was 522 (interquartile range [IQR] 306-720); 35% of people had undetectable HIV RNA. Patients had been taking HAART for a median of 53 months (IQR 33-62). Among enrolled patients, 83 (47%) had a diagnosis of self-reported MOA; 57 of them reported body changes of more than 12 months duration. Forty persons (23%) self-reported nonadherence in the previous week. Mean time on HAART was 48.7 months (SD = 19.7) for people with MOA and 42.1 months (SD = 21.8) for those without MOA (p =.043). The odds of adherence for people with MOA was 2.36 times (95% CI 1.11-5.00) higher than for people without MOA. On multivariate analysis, being older and female, having an undetectable HIV RNA, longer duration on HAART, and self-reported adherence were independently associated with the presence of MOA. In people with MOA, adherence seems to decrease over time. CONCLUSION: Longer time on HAART and self-reported adherence were correlated to MOA. MOA was also associated with older age and female gender.
Authors: G Guaraldi; G Orlando; R Murri; M Vandelli; M De Paola; B Beghetto; G Nardini; S Ciaffi; F Vichi; A W Wu Journal: Qual Life Res Date: 2006-02 Impact factor: 4.147
Authors: Marisela Noorhasan; Daniel R Drozd; Carl Grunfeld; Joseph O Merrill; Greer A Burkholder; Michael J Mugavero; James H Willig; Amanda L Willig; Karen L Cropsey; Kenneth H Mayer; Aaron Blashill; Matthew Mimiaga; Mary E McCaul; Heidi Hutton; Geetanjali Chander; William C Mathews; Sonia Napravnik; Joseph J Eron; Katerina Christopoulos; Rob J Fredericksen; Robin M Nance; Joseph Chris Delaney; Paul K Crane; Michael S Saag; Mari M Kitahata; Heidi M Crane Journal: AIDS Res Hum Retroviruses Date: 2017-02-16 Impact factor: 2.205
Authors: Giovanni Guaraldi; Rita Murri; Gabriella Orlando; Chiara Giovanardi; Nicola Squillace; Marcella Vandelli; Barbara Beghetto; Giulia Nardini; Maria De Paola; Roberto Esposito; Albert W Wu Journal: AIDS Patient Care STDS Date: 2008-07 Impact factor: 5.078
Authors: Charlotte M Verolet; Cécile Delhumeau-Cartier; Marlène Sartori; Simona Toma; Sophie Zawadynski; Minerva Becker; Enos Bernasconi; Laurence Toutous Trellu; Alexandra Calmy Journal: AIDS Res Ther Date: 2015-06-20 Impact factor: 2.250
Authors: Aline Francielle Mota Segatto; Ismael Forte Freitas; Vanessa Ribeiro Dos Santos; Kelly Cristina de Lima Ramos Pinto Alves; Dulce Aparecida Barbosa; Alexandre Martins Portelinha Filho; Henrique Luiz Monteiro Journal: BMC Res Notes Date: 2012-10-02